TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
We envision a world where Epithelioid Hemangioendothelioma (EHE) is easily diagnosed and treatable. Join our dedicated community by subscribing to our emails.
EMPOWER YOURSELF WITH KNOWLEDGE
Upcoming Foundation Events
Quick Links
Patients
Community
Latest EHE News, Events and Research
The Pledge: Edition 40, Q1 – January-March, 2025
Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe provide content including research news, patient and fundraising stories, and much more. Click here to view the most recent edition of the online EHE newsletter, The Pledge.
ASCO 2025 Recap: Advancing Research to Conquer Cancer
Denise Robinson, EHE Foundation Executive Director and Director of Research, had the privilege of representing the Foundation at the 2025 ASCO Annual Meeting in Chicago, where tens of thousands of global oncology professionals gathered to share knowledge with a purposeful commitment to conquer cancer. The American Society of Clinical Oncology (ASCO) is the world’s leading […]
The EHE Foundation Welcomes Two New Board Members
The EHE Foundation is proud to announce the addition of two new members to our Board of Directors: Hollace D. Leppert, DO, FACOI, and Krista Sheeley, BSN, RN. Both bring extensive healthcare experience, leadership, and passion to our mission. We are excited to welcome them to the EHE Foundation and look forward to their insight, […]
Celebrating Progress and Hope: 2025 EHE 360 Global Patient Conference Recap
The EHE Foundation is proud to celebrate the success of the 2025 EHE 360 Global Patient Conference, a truly transformative event that brought together the global EHE community for learning, collaboration, and connection. Over 200 participants from a record 25 countries were united by a common mission to drive progress in EHE research, treatment, and […]
Fueling Hope Through Research: Celebrating National Cancer Research Month
May is National Cancer Research Month, a time to honor the scientists, clinicians, and collaborators who are moving us closer to effective treatments and a cure for epithelioid hemangioendothelioma (EHE). Research is the EHE Foundation’s highest priority in our mission to find effective treatments and ultimately a cure for EHE. With no standard treatment available, […]
Strengthening Global Collaboration in Sarcoma: Highlights from the 2025 SPAGN Annual Conference
From April 11–13, 2025, representatives of The EHE Foundation participated in the 15th Annual Conference of the Sarcoma Patient Advocacy Global Network (SPAGN), marking SPAGN’s first conference in the United States. The National Cancer Institute (NCI) co-hosted the event, underscoring the importance of international collaboration in sarcoma advocacy. Denise Robinson commented, “As a long-time supporter […]
The Pledge: Edition 43, Q4 – October-December, 2025
Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe provide content, including research news, patient and fundraising stories, and much more. Click here to view the most recent edition of the online EHE newsletter, The Pledge.
Understanding Quality of Life for People Living With EHE
The European Organisation of Research and Treatment of Cancer (EORTC) is conducting research to better understand health-related quality of life (HRQoL) concerns among people living with rare cancers. Recently, researchers analyzed results from a group of 31 people with EHE from 11 different countries who participated in the study. The findings showed that pain–and the […]
Exploring Eribulin as a Potential Treatment Option for EHE
Prior research has shown that a class of medications called microtubule inhibitors may be effective at controlling the growth of EHE tumors. Recently, researchers conducted a phase 2 study to test whether the microtubule inhibitor eribulin is a safe and effective way to treat patients whose tumors continued to grow after prior treatment. Six (6) […]